Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Alcohol-Related liver disease: drug trial targets inflammation

NCT ID NCT06613698

Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This study tests a new drug, GSK4532990, in about 393 adults with liver inflammation from alcohol use. The goal is to see if it safely reduces liver stiffness and improves liver function over 52 weeks. Participants receive either the drug or a placebo, and researchers monitor side effects and blood levels of the drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 393 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Capable of giving signed informed consent prior to the performance of any study-specific procedures. * Able and willing to comply with all study assessments and adhere to the protocol schedule of activities. * In the opinion of the investigator, there is a history of alcohol consumption compatible with either ALD or Met ALD. * A female participant is eligible to participate after meeting additional pre-defined criteria. * Participants must meet predefined stable use requirements of concomitant medications based on study criteria. * Participant has advanced chronic liver disease Exclusion Criteria: * Meeting any definition of organ system failure as defined by the North American Consortium for Study of End-stage Liver Disease (NACSELD) * Exceeding pre-defined biochemical parameters for Alanine Aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline Phosphatase (ALP), Platelets, International normalised ratio (INR), Albumin, estimated glomerular filtration rate (eGFR), Urine albumin-creatinine ratio (UACR) or Glycosylated Hemoglobin (HbA1c). Other primary causes of liver disease based on study criteria. * Current malignancy (except for basal cell carcinoma or uterine carcinoma-in-situ) at screening. Participants under evaluation for possible malignancy at screening are not eligible. * Prior organ transplant or current listing or active consideration for organ transplant during the screening period (except for corneal transplants). * Chronic or acute, including partial, known portal vein thrombosis. * Prior transjugular intrahepatic portosystemic shunt (TIPSS) insertion. * Any acute cardiovascular event including myocardial infarction, unstable angina, symptomatic heart failure, or cerebrovascular accident in the 6 months prior to screening. * Poorly controlled hypertension * Clinical suspicion of rhabdomyolysis during the screening period * Clinical suspicion of a bleeding episode during the screening period related to portal hypertension and/or low blood fibrinogen level. * Body Mass Index (BMI) \>35 kg/m2 at screening * Any liver-related clinical event that started (onset) \<8 weeks prior to Baseline (D1).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liver diseases, alcoholic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alcoholic liver disease fatty liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver diseases, alcoholic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    138 sites in 18 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • GSK Investigational Site

    RECRUITING

    Chandler, Arizona, 85224, United States

  • GSK Investigational Site

    RECRUITING

    Phoenix, Arizona, 85006, United States

  • GSK Investigational Site

    RECRUITING

    Tucson, Arizona, 85712, United States

  • GSK Investigational Site

    RECRUITING

    Tucson, Arizona, 85715, United States

  • GSK Investigational Site

    RECRUITING

    Coronado, California, 92118, United States

  • GSK Investigational Site

    RECRUITING

    Lancaster, California, 93534, United States

  • GSK Investigational Site

    RECRUITING

    Los Angeles, California, 90033, United States

  • GSK Investigational Site

    RECRUITING

    Los Angeles, California, 90048, United States

  • GSK Investigational Site

    RECRUITING

    Pasadena, California, 91105, United States

  • GSK Investigational Site

    RECRUITING

    Sacramento, California, 95817, United States

  • GSK Investigational Site

    RECRUITING

    Brandon, Florida, 33511, United States

  • GSK Investigational Site

    RECRUITING

    Miami, Florida, 33173, United States

  • GSK Investigational Site

    RECRUITING

    Miami Lakes, Florida, 33016, United States

  • GSK Investigational Site

    RECRUITING

    Atlanta, Georgia, 30309, United States

  • GSK Investigational Site

    RECRUITING

    Indianapolis, Indiana, 46202, United States

  • GSK Investigational Site

    RECRUITING

    Topeka, Kansas, 66606, United States

  • GSK Investigational Site

    RECRUITING

    Marrero, Louisiana, 70072, United States

  • GSK Investigational Site

    RECRUITING

    Detroit, Michigan, 48202, United States

  • GSK Investigational Site

    RECRUITING

    Las Vegas, Nevada, 89106, United States

  • GSK Investigational Site

    RECRUITING

    New York, New York, 10029, United States

  • GSK Investigational Site

    RECRUITING

    Chapel Hill, North Carolina, 27514, United States

  • GSK Investigational Site

    RECRUITING

    Cleveland, Ohio, 44195, United States

  • GSK Investigational Site

    RECRUITING

    Philadelphia, Pennsylvania, 19014, United States

  • GSK Investigational Site

    RECRUITING

    Hermitage, Tennessee, 37076, United States

  • GSK Investigational Site

    RECRUITING

    Arlington, Texas, 76012, United States

  • GSK Investigational Site

    RECRUITING

    Austin, Texas, 78757, United States

  • GSK Investigational Site

    RECRUITING

    Dallas, Texas, 75203, United States

  • GSK Investigational Site

    RECRUITING

    Dallas, Texas, 75390-8565, United States

  • GSK Investigational Site

    RECRUITING

    Fort Worth, Texas, 76104, United States

  • GSK Investigational Site

    RECRUITING

    Georgetown, Texas, 78626, United States

  • GSK Investigational Site

    COMPLETED

    McAllen, Texas, 78503, United States

  • GSK Investigational Site

    RECRUITING

    San Antonio, Texas, 78215, United States

  • GSK Investigational Site

    RECRUITING

    Richmond, Virginia, 23219, United States

  • GSK Investigational Site

    RECRUITING

    Richmond, Virginia, 23249, United States

  • GSK Investigational Site

    RECRUITING

    Buenos Aires, 1425, Argentina

  • GSK Investigational Site

    RECRUITING

    Buenos Aires, C1061AAS, Argentina

  • GSK Investigational Site

    RECRUITING

    Buenos Aires, C1181ACH, Argentina

  • GSK Investigational Site

    RECRUITING

    Buenos Aires, Argentina

  • GSK Investigational Site

    RECRUITING

    Ciudad AutOnoma de Buenos Aire, 1118, Argentina

  • GSK Investigational Site

    RECRUITING

    Ciudad Autonoma de Buenos Aire, C1426, Argentina

  • GSK Investigational Site

    RECRUITING

    Rosario, 2002, Argentina

  • GSK Investigational Site

    RECRUITING

    Rosario, S2002, Argentina

  • GSK Investigational Site

    RECRUITING

    San Miguel de Tucumán, T4000IHE, Argentina

  • GSK Investigational Site

    RECRUITING

    Adelaide, South Australia, 5000, Australia

  • GSK Investigational Site

    RECRUITING

    Melbourne, Victoria, 3004, Australia

  • GSK Investigational Site

    RECRUITING

    Parkville Melbourne, Victoria, 3050, Australia

  • GSK Investigational Site

    RECRUITING

    Murdoch, Western Australia, 6150, Australia

  • GSK Investigational Site

    RECRUITING

    Perth, Western Australia, 6000, Australia

  • GSK Investigational Site

    RECRUITING

    Calgary, Alberta, T2N 4Z6, Canada

  • GSK Investigational Site

    RECRUITING

    New Westminster, British Columbia, V3L 3W4, Canada

  • GSK Investigational Site

    RECRUITING

    Vancouver, British Columbia, V6Z 2K5, Canada

  • GSK Investigational Site

    RECRUITING

    London, Ontario, N6A 5A5, Canada

  • GSK Investigational Site

    RECRUITING

    Toronto, Ontario, M1S 4T7, Canada

  • GSK Investigational Site

    RECRUITING

    Toronto, Ontario, M5G 2C4, Canada

  • GSK Investigational Site

    RECRUITING

    Montreal, Quebec, H2X 0A9, Canada

  • GSK Investigational Site

    RECRUITING

    Terrebonne, Quebec, J6X 4P7, Canada

  • GSK Investigational Site

    RECRUITING

    Esbjerg, 6700, Denmark

  • GSK Investigational Site

    RECRUITING

    Hvidovre, 2650, Denmark

  • GSK Investigational Site

    RECRUITING

    Odense C, 5000, Denmark

  • GSK Investigational Site

    RECRUITING

    Angers, 49933, France

  • GSK Investigational Site

    RECRUITING

    Bobigny, 93000, France

  • GSK Investigational Site

    RECRUITING

    Créteil, 94000, France

  • GSK Investigational Site

    RECRUITING

    Lille, 59037, France

  • GSK Investigational Site

    RECRUITING

    Montpellier, 34295, France

  • GSK Investigational Site

    RECRUITING

    Rouen, 76031, France

  • GSK Investigational Site

    RECRUITING

    Bochum, North Rhine-Westphalia, 44892, Germany

  • GSK Investigational Site

    RECRUITING

    Berlin, 10787, Germany

  • GSK Investigational Site

    RECRUITING

    Berlin, 13353, Germany

  • GSK Investigational Site

    RECRUITING

    Kiel, 24105, Germany

  • GSK Investigational Site

    RECRUITING

    Leipzig, 04103, Germany

  • GSK Investigational Site

    RECRUITING

    Mainz, 55101, Germany

  • GSK Investigational Site

    RECRUITING

    Athens, 10676, Greece

  • GSK Investigational Site

    RECRUITING

    Athens, 11527, Greece

  • GSK Investigational Site

    RECRUITING

    Athens, 11527, Greece

  • GSK Investigational Site

    RECRUITING

    Bergamo, 24127, Italy

  • GSK Investigational Site

    RECRUITING

    Bologna, 40138, Italy

  • GSK Investigational Site

    RECRUITING

    Messina, 98124, Italy

  • GSK Investigational Site

    RECRUITING

    Milan, 20122, Italy

  • GSK Investigational Site

    RECRUITING

    Milan, 20142, Italy

  • GSK Investigational Site

    RECRUITING

    Milan, 20162, Italy

  • GSK Investigational Site

    RECRUITING

    Padova, 35131, Italy

  • GSK Investigational Site

    RECRUITING

    Roma, 00128, Italy

  • GSK Investigational Site

    RECRUITING

    Roma, 00168, Italy

  • GSK Investigational Site

    RECRUITING

    Chiba, 286-8520, Japan

  • GSK Investigational Site

    RECRUITING

    Ehime, 790-0024, Japan

  • GSK Investigational Site

    RECRUITING

    Gunma, 371-8511, Japan

  • GSK Investigational Site

    RECRUITING

    Hokkaido, 060-0033, Japan

  • GSK Investigational Site

    WITHDRAWN

    Kagawa, 760-0017, Japan

  • GSK Investigational Site

    RECRUITING

    Kagawa, 761-0793, Japan

  • GSK Investigational Site

    RECRUITING

    Nara, 634-8522, Japan

  • GSK Investigational Site

    RECRUITING

    Niigata, 951-8520, Japan

  • GSK Investigational Site

    RECRUITING

    Osaka, 545-8586, Japan

  • GSK Investigational Site

    RECRUITING

    Osaka, 564-0013, Japan

  • GSK Investigational Site

    RECRUITING

    Osaka, 565-0871, Japan

  • GSK Investigational Site

    RECRUITING

    Saitama, 350-0495, Japan

  • GSK Investigational Site

    RECRUITING

    Shizuoka, 431-3192, Japan

  • GSK Investigational Site

    RECRUITING

    Tokyo, 180-8610, Japan

  • GSK Investigational Site

    RECRUITING

    DF, 14080, Mexico

  • GSK Investigational Site

    RECRUITING

    Mexico City, 11510, Mexico

  • GSK Investigational Site

    RECRUITING

    San Pedro Garza García, 66260, Mexico

  • GSK Investigational Site

    RECRUITING

    Katowice, 40-600, Poland

  • GSK Investigational Site

    RECRUITING

    Mysłowice, 41-400, Poland

  • GSK Investigational Site

    RECRUITING

    Warsaw, 00-124, Poland

  • GSK Investigational Site

    RECRUITING

    Johannesburg, 2193, South Africa

  • GSK Investigational Site

    RECRUITING

    Soweto Johannesburg, 2013, South Africa

  • GSK Investigational Site

    RECRUITING

    Ansan, 15355, South Korea

  • GSK Investigational Site

    RECRUITING

    Bucheon-si, South Korea

  • GSK Investigational Site

    RECRUITING

    Daegu, 700-721, South Korea

  • GSK Investigational Site

    RECRUITING

    Seoul, 02447, South Korea

  • GSK Investigational Site

    RECRUITING

    Seoul, 06351, South Korea

  • GSK Investigational Site

    RECRUITING

    Seoul, 07061, South Korea

  • GSK Investigational Site

    RECRUITING

    Seoul, 138-736, South Korea

  • GSK Investigational Site

    RECRUITING

    Suwon Gyeonggi-do, 442-723, South Korea

  • GSK Investigational Site

    RECRUITING

    Barcelona, 08003, Spain

  • GSK Investigational Site

    RECRUITING

    Barcelona, 08035, Spain

  • GSK Investigational Site

    RECRUITING

    Barcelona, 08036, Spain

  • GSK Investigational Site

    RECRUITING

    León, 24071, Spain

  • GSK Investigational Site

    RECRUITING

    Madrid, 28006, Spain

  • GSK Investigational Site

    RECRUITING

    Madrid, 28007, Spain

  • GSK Investigational Site

    RECRUITING

    Madrid, 28041, Spain

  • GSK Investigational Site

    RECRUITING

    Santander, 39011, Spain

  • GSK Investigational Site

    RECRUITING

    Seville, 41013, Spain

  • GSK Investigational Site

    RECRUITING

    Valencia, 46014, Spain

  • GSK Investigational Site

    RECRUITING

    Valladolid, 47003, Spain

  • GSK Investigational Site

    RECRUITING

    Vigo, 36071, Spain

  • GSK Investigational Site

    RECRUITING

    Stockholm, SE-141 86, Sweden

  • GSK Investigational Site

    RECRUITING

    Uppsala, 751 85, Sweden

  • GSK Investigational Site

    RECRUITING

    Kocaeli, İzmit, 41001, Turkey (Türkiye)

  • GSK Investigational Site

    RECRUITING

    Diyarbakır, Sur, 21280, Turkey (Türkiye)

  • GSK Investigational Site

    RECRUITING

    Adana, Yüreğir, 01230, Turkey (Türkiye)

  • GSK Investigational Site

    RECRUITING

    Istanbul, 34010, Turkey (Türkiye)

  • GSK Investigational Site

    RECRUITING

    Bristol, BS10 5NB, United Kingdom

  • GSK Investigational Site

    RECRUITING

    Cambridge, CB2 0QQ, United Kingdom

  • GSK Investigational Site

    RECRUITING

    Glasgow Strathclyde, G51 4TF, United Kingdom

  • GSK Investigational Site

    RECRUITING

    Leeds West Yorkshire, LS9 7TF, United Kingdom

  • GSK Investigational Site

    RECRUITING

    Liverpool, L9 7AL, United Kingdom

  • GSK Investigational Site

    RECRUITING

    London, NW3 2QG, United Kingdom

  • GSK Investigational Site

    RECRUITING

    London, W2 1NY, United Kingdom

  • GSK Investigational Site

    RECRUITING

    Middlesbrough, TS4 3BW, United Kingdom

  • GSK Investigational Site

    RECRUITING

    Plymouth, PL6 5FP, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.